Literature DB >> 10092820

Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes.

L Ottonello1, G Tortolina, M Amelotti, F Dallegri.   

Abstract

It has been recently shown that Fas ligand (FasL) expression on islet beta grafts results in neutrophilic infiltration and graft rejection. In this study, we show that human recombinant soluble FasL is endowed with potent chemotactic properties toward human neutrophilic polymorphonuclear leukocytes (neutrophils) at concentrations incapable of inducing cell apoptosis. Furthermore, neutrophils exposed to soluble FasL did not display detectable change of intracellular Ca2+ and did not undergo superoxide production or exocytosis of primary and secondary granules. Our results show that FasL is a potent chemoattractant for human neutrophils without evoking their secretory responses. This finding suggests a novel proinflammatory function for this ligand and may help to clarify the mechanism governing FasL-mediated graft rejection, thereby offering rational bases for controlling and modulating FasL-based immunotherapies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10092820

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

Review 1.  New approaches to inducing the death of alloreactive lymphocytes.

Authors:  S M Krams
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

Review 2.  Peculiarities of cell death mechanisms in neutrophils.

Authors:  B Geering; H-U Simon
Journal:  Cell Death Differ       Date:  2011-06-03       Impact factor: 15.828

3.  Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice.

Authors:  Esma S Yolcu; Hong Zhao; Laura Bandura-Morgan; Chantale Lacelle; Kyle B Woodward; Nadir Askenasy; Haval Shirwan
Journal:  J Immunol       Date:  2011-11-07       Impact factor: 5.422

4.  Pancreatic islets engineered with a FasL protein induce systemic tolerance at the induction phase that evolves into long-term graft-localized immune privilege.

Authors:  Kyle B Woodward; Hong Zhao; Pradeep Shrestha; Lalit Batra; Min Tan; Orlando Grimany-Nuno; Laura Bandura-Morgan; Nadir Askenasy; Haval Shirwan; Esma S Yolcu
Journal:  Am J Transplant       Date:  2020-01-05       Impact factor: 8.086

5.  Rabies virus ocular disease: T-cell-dependent protection is under the control of signaling by the p55 tumor necrosis factor alpha receptor, p55TNFR.

Authors:  S Camelo; J Castellanos; M Lafage; M Lafon
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

6.  Mechanisms underlying reduced responsiveness of neonatal neutrophils to distinct chemoattractants.

Authors:  B Weinberger; D L Laskin; T M Mariano; V R Sunil; C J DeCoste; D E Heck; C R Gardner; J D Laskin
Journal:  J Leukoc Biol       Date:  2001-12       Impact factor: 4.962

7.  Proinflammatory consequences of transgenic fas ligand expression in the heart.

Authors:  D P Nelson; E Setser; D G Hall; S M Schwartz; T Hewitt; R Klevitsky; H Osinska; D Bellgrau; R C Duke; J Robbins
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

8.  The regulation of FasL expression during activation-induced cell death (AICD).

Authors:  T Nguyen; J Russell
Journal:  Immunology       Date:  2001-08       Impact factor: 7.397

9.  Fas ligand-induced murine pulmonary inflammation is reduced by a stable decoy receptor 3 analogue.

Authors:  Mark A Wortinger; Joseph W Foley; Patrick Larocque; Derrick R Witcher; Michael Lahn; Joseph A Jakubowski; Andrew Glasebrook; Ho Yeong Song
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

Review 10.  The effector T cell response to influenza infection.

Authors:  Matthew M Hufford; Taeg S Kim; Jie Sun; Thomas J Braciale
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.